Serum and cerebrospinal fluid S100B, neuron-specific enolase, and total tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion: A diagnostic validity
Pediatrics International, 04/30/2012
Shiihara T et al. – The combination of CSF S100B and CSF total tau protein resulted in a positive predictive value of Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) 83.3%, which could be helpful for early diagnosis, facilitating early therapeutic interventions.
The authors measured and compared the serum or cerebrospinal fluid (CSF) levels of S100B, neuron-specific enolase (NSE), and total tau protein in 43 patients with FS and 18 patients with AESD, at any point during the disease.
To assess early diagnostic validity, they compared these biomarkers in 43 FS and eight AESD patients, with whom the day 0–2 samples were available.
The levels of all biomarkers were significantly higher in AESD than FS patients.
When only day 0–2 samples from AESD patients were used, the levels of all the measured biomarkers, except serum NSE, were still significantly higher in patients with AESD than in FS, suggesting that AESD could damage astrocytes, neurons, and axons, even in the early stages of the disease.
According to the receiver–operator characteristic curve analyses, CSF S100B (cut-off value, 100 pg/mL) and CSF total tau protein (cut-off value, 100 pg/mL) were better predictors of AESD than other biomarkers.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.